ALT logo

ALT Altimmune, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$1.41
+0.02 (+1.44%)

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-al…

Market Cap: $274.37Maltimmune.com

Price

No data yet.

Social Signal Score

47
5d
50
1 mentions
—
30d
43
7 mentions
—
60d
48
10 mentions
—
90d
48
13 mentions
—
news: 13

Analyst Ratings

15 analysts
Buyconsensus
Strong Buy 0Buy 12Hold 3Sell 0Strong Sell 0
Avg price target$10+609.2%
Low $10Median $10High $10
Current Consensus

Revenue

$0.00-100.00%
$-110.0K$1.46M$3.02M$4.59M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.98
$-1.03–$-0.96
6 analysts
FY2026
$-0.62
$-0.69–$-0.54
7 analysts
FY2027
$-0.68
$-0.85–$-0.54
7 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Jerome Benedict Durso
Sector
Healthcare
Industry
Biotechnology
Employees
57
Beta
0.18
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
1.04
altimmune.com